New treatments to slow down Alzheimer's disease
Novel Disease-modifying Small Molecules for Treatment of Alzheimer's Disease”
This study is looking at new ways to help people with Alzheimer's by targeting a protein that may be causing memory problems, with the hope of improving thinking skills and slowing down the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Minneapolis VA Medical Center NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11013850 on NIH RePORTER |
What this research studies
This research focuses on developing new small molecules that target a protein called synaptojanin 1, which is linked to cognitive decline in Alzheimer's disease. By reducing the levels of this protein, the study aims to improve cognitive function and slow the progression of neurodegeneration associated with Alzheimer's. The approach involves understanding how synj1 affects brain health and exploring its potential as a therapeutic target. Patients may benefit from innovative treatments that could alter the course of their disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those with genetic factors such as APOE4 that may influence disease progression.
Not a fit: Patients with other forms of dementia or those without a diagnosis of Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly slow the progression of Alzheimer's disease and improve cognitive function.
How similar studies have performed: Previous research has shown promising results in targeting synaptojanin 1 for cognitive improvement in Alzheimer's, indicating potential for success in this novel approach.
Where this research is happening
Minneapolis, United States
- Minneapolis VA Medical Center — Minneapolis, United States (Active)
Researchers
- Principal investigator: Cai, Dongming — Minneapolis VA Medical Center
- Study coordinator: Cai, Dongming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.